NDLI: Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study.

Please wait, while we are loading the content...

Impact of substance use disorders on recovery from episodes of depression in bipolar disorder patients: prospective data from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD).

Association of Western and traditional diets with depression and anxiety in women.

The psychiatric sequelae of traumatic injury.

Does the DSM-IV clinical significance criterion for major depression reduce false positives? Evidence from the National Comorbidity Survey Replication.

An FMRI study of frontostriatal circuits during the inhibition of eye blinking in persons with Tourette syndrome.

Psychiatric disorders in preschool offspring of parents with bipolar disorder: the Pittsburgh Bipolar Offspring Study (BIOS).

Normalizing effects of modafinil on sleep in chronic cocaine users.

Prenatal infection and schizophrenia: a review of epidemiologic and translational studies.

Psychiatrists' role in the health of the pregnant mother and the risk for schizophrenia in her offspring.

Combining antidepressant medications: a good idea?

Nutrition and psychiatry.

Normalizing effects of modafinil on cocaine-induced sleep abnormalities.

Assuring that double-blind is blind.

Psychiatric assessment of aggressive patients: a violent attack on a resident.

The foundation of the first Western mental asylum.

Successful clozapine retrial after suspected myocarditis.

Oseltamivir-induced mania in a patient with H1N1.

Remission of drug-induced hepatitis after switching from risperidone to paliperidone.

Subjective adjustment of individuals with psychiatric disorders in the aftermath of the L'Aquila earthquake.

Psychosis following excessive ingestion of energy drinks in a patient with schizophrenia.

Year: 2010 Volume: 167 Issue: 2

Year: 2010 Volume: 167 Issue: 1

Year: 2009 Volume: 166

Year: 2008 Volume: 165

Year: 2007 Volume: 164

Year: 2006 Volume: 163

Year: 2005 Volume: 162

Year: 2004 Volume: 161

Year: 2003 Volume: 160

Year: 2002 Volume: 159

Year: 2001 Volume: 158

Year: 2000 Volume: 157

Year: 1999 Volume: 156

Year: 1998 Volume: 155

Year: 1997 Volume: 154

Year: 1995 Volume: 152

Year: 1994 Volume: 151

Year: 1985 Volume: 142

Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Blier, Pierre Ward, Herbert E. Tremblay, Philippe Laberge, Louise Hébert, Chantal Bergeron, Richard
Description	Author Affiliation: Blier P ( University of Ottawa Institute of Mental Health Research, University of Ottawa, Ottawa, Ontario, Canada K1Z 7K4. pierre.blier@rohcg.on.ca)
Abstract	OBJECTIVE: Various classes of antidepressant medications generally induce remission of major depressive disorder in only about one-third of patients. In a previous study using mirtazapine or paroxetine alone or in combination from treatment initiation, the rate of patients who remitted within a 6-week period was twice that of patients using either drug alone. In this double-blind study, the authors sought to produce evidence for the superiority of different combinations of antidepressant drugs from treatment initiation. METHOD: Patients (N=105) meeting DSM-IV criteria for major depressive disorder were randomly assigned to receive, from treatment initiation, either fluoxetine monotherapy (20 mg/day) or mirtazapine (30 mg/day) in combination with fluoxetine (20 mg/day), venlafaxine (225 mg/day titrated in 14 days), or bupropion (150 mg/day) for 6 weeks. The primary outcome measure was the Hamilton Depression Rating Scale (HAM-D) score. RESULTS: The overall dropout rate was 15%, without notable differences among the four groups. Compared with fluoxetine monotherapy, all three combination groups had significantly greater improvements on the HAM-D. Remission rates (defined as a HAM-D score of 7 or less) were 25% for fluoxetine, 52% for mirtazapine plus fluoxetine, 58% for mirtazapine plus venlafaxine, and 46% for mirtazapine plus bupropion. Among patients who had a marked response, double-blind discontinuation of one agent produced a relapse in about 40% of cases. CONCLUSIONS: The combination treatments were as well tolerated as fluoxetine monotherapy and more clinically effective. The study results, which add to a growing body of evidence, suggest that use of antidepressant combinations from treatment initiation may double the likelihood of remission compared with use of a single medication.
File Format	HTM / HTML
ISSN	0002953X
e-ISSN	15357228
Journal	American Journal of Psychiatry
Issue Number	3
Volume Number	167
Language	English
Publisher	American Psychiatric Association
Publisher Date	2010-03-01
Publisher Place	United States
Access Restriction	Open
Subject Keyword	Discipline Psychiatry Antidepressive Agents Therapeutic Use Bupropion Cyclohexanols Depressive Disorder, Major Drug Therapy Fluoxetine Mianserin Analogs & Derivatives Adverse Effects Double-blind Method Drug Therapy, Combination Personality Inventory Statistics & Numerical Data Psychometrics Secondary Prevention Venlafaxine Hydrochloride Comparative Study Multicenter Study Randomized Controlled Trial Research Support, Non-u.s. Gov't
Content Type	Text
Resource Type	Article
Subject	Psychiatry and Mental Health

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Combining antidepressant medications: a good idea?

Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study.

Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.

Double-blind, placebo-controlled comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.

Depression Subtypes in Predicting Antidepressant Response: A Report From the iSPOT-D Trial.

Venlafaxine for major depression.

Curcumin as an add-on to antidepressive treatment: a randomized, double-blind, placebo-controlled, pilot clinical study.

Baseline depression severity as a predictor of single and combination antidepressant treatment outcome: results from the CO-MED trial.

Effects of venlafaxine and fluoxetine on lymphocyte subsets in patients with major depressive disorder: a flow cytometric analysis.

Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study.

Similar Documents

Combining antidepressant medications: a good idea?

Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study.

Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.

Double-blind, placebo-controlled comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.

Depression Subtypes in Predicting Antidepressant Response: A Report From the iSPOT-D Trial.

Venlafaxine for major depression.

Curcumin as an add-on to antidepressive treatment: a randomized, double-blind, placebo-controlled, pilot clinical study.

Baseline depression severity as a predictor of single and combination antidepressant treatment outcome: results from the CO-MED trial.

Effects of venlafaxine and fluoxetine on lymphocyte subsets in patients with major depressive disorder: a flow cytometric analysis.

Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study.